Ten challenges and opportunities in computational immuno-oncology.

Immuno-oncology has transformed the treatment of cancer, with several immunotherapies becoming the standard treatment across histologies. Despite these advancements, the majority of patients do not experience durable clinical benefits, highlighting the imperative for ongoing advancement in immuno-oncology. Computational immuno-oncology emerges as a forefront discipline that draws on biomedical data science and intersects with oncology, immunology, and clinical research, with the overarching goal to accelerate the development of effective and safe immuno-oncology treatments from the laboratory to the clinic. In this review, we outline 10 critical challenges and opportunities in computational immuno-oncology, emphasizing the importance of robust computational strategies and interdisciplinary collaborations amid the constantly evolving interplay between clinical needs and technological innovation.

Informations de copyright

© Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

Déclaration de conflit d'intérêts

Competing interests: RB declares PCT/US15/612657 (Cancer Immunotherapy), PCT/US18/36052 (Microbiome Biomarkers for Anti-PD-1/PD-L1 Responsiveness: Diagnostic, Prognostic and Therapeutic Uses Thereof), PCT/US63/055227 (Methods and Compositions for Treating Autoimmune and Allergic Disorders). AM is an equity holder in Picture Health, Elucid Bioimaging, and Inspirata. Currently, he serves on the advisory board of Picture Health, and SimBioSys. He currently consults for Takeda; He also has sponsored research agreements with AstraZeneca and Bristol Myers-Squibb; his technology has been licensed to Picture Health and Elucid Bioimaging; he is also involved in two different R01 grants with Inspirata; he also serves as a member for the Frederick National Laboratory Advisory Committee.VDJ has performed consulting for VincerX Pharmaceuticals, Providence St. John, Los Angeles; she is a founder of Bioinformatica. JSB-S, EK, DM are full time, paid employees of NCI/NIH. EJF is on the Scientific Advisory Board of Resistance Bio, a consultant for Mestag and Merck, and receives research funding from AbbVie. SG reports current and past research funding from Regeneron Pharmaceuticals, Boehringer Ingelheim, BMS (Celgene), Genentech, EMD Serono, Pfizer, and Takeda. ER is a co-founder of MedAware, Metabomed and Pangea Biomed (divested), and an unpaid member of Pangea Biomed’s and GSK Oncology scientific advisory boards. DVV is a co-founder and chief scientist of Barrier Biosciences and holds equity in the company. NV is on the Consulting/Advisory Boards of Sanofi/Genzyme (2022), Oncocyte (2021), Eli Lilly (2021), Regeneron (2022), Amgen (2023), Xencor (2023), AstraZeneca (2023), Tempus (2023), Pfizer (2024), Summit Therapeutics (2024), OncoHost (2024); she reports travel reimbursement from Regeneron; research grants from Oncocyte (2022–), Circulogene and Mirati, funding from Circulogene, and honoraria from Nebraska Oncology Society, Scienomics Group, Grace, OncLive and OMNI-Oncology. EMVA reports personal fees from Tango Therapeutics, Genome Medical, Genomic Life, Monte Rosa Therapeutics, Manifold Bio, Enara Bio, Riva Therapeutics, Foaley & Hoag, and Serinus Bio, grants and personal fees from Novartis Institute for Biomedical Research, and grants from BMS, Janssen, and Sanofi outside the submitted work; in addition, EMVA has a patent for institutional patents filed on chromatin mutations and immunotherapy response and methods for clinical interpretation pending.